scispace - formally typeset
A

Anna Klioueva

Researcher at Binghamton University

Publications -  6
Citations -  366

Anna Klioueva is an academic researcher from Binghamton University. The author has contributed to research in topics: Dyskinesia & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 124 citations.

Papers
More filters
Journal ArticleDOI

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021

TL;DR: The highest impact of booster doses against infection and death compared with full vaccination without booster doses was recorded among persons aged 50-64 and ≥65 years, and eligibility to stay up to date with COVID-19 vaccinations.
Journal ArticleDOI

Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

TL;DR: It is demonstrated that moderate NE loss reduced the development and expression of AIMs and rotations but not L-DOPA efficacy while anti-dyskinetic efficacy of α2- and β-adrenergic receptor blockade was maintained.
Journal ArticleDOI

Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat

TL;DR: Combined subthreshold doses of ±8-OH-DPAT and MK-801 dose-dependently decreased l-DOPA-induced AIMs without affecting rotations and indicate a functional interaction between 5-HT1AR and NMDAR that may improve pharmacological treatment of PD patients.
Journal ArticleDOI

Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.

TL;DR: It is suggested that 5-HT1B receptor stimulation directly diminishes D1 receptor-mediated dyskinesia, implicating an important target for the treatment of L-DOPA-induced dysklesia.